Abstract
The synthesis and biological evaluation of novel Tie-2 kinase inhibitors are presented. Based on the pyrrolopyrimidine chemotype, several new series are described, including the benzimidazole series by linking a benzimidazole to the C5-position of the 4-amino-pyrrolopyrimidine core and the ketophenyl series synthesized by incorporating a ketophenyl group to the C5-position. Medicinal chemistry efforts led to potent Tie-2 inhibitors. Compound 15, a ketophenyl pyrrolopyrimidine urea analog with improved physicochemical properties, demonstrated favorable in vitro attributes as well as dose responsive and robust oral tumor growth inhibition in animal models.
Copyright © 2013 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Dose-Response Relationship, Drug
-
Drug Discovery*
-
Humans
-
Male
-
Molecular Structure
-
Neoplasms / drug therapy*
-
Neoplasms / enzymology
-
Neoplasms / pathology
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / chemical synthesis*
-
Protein Kinase Inhibitors / pharmacology*
-
Pyrimidines / chemical synthesis
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology*
-
Pyrroles / chemical synthesis
-
Pyrroles / chemistry
-
Pyrroles / pharmacology*
-
Rats
-
Rats, Sprague-Dawley
-
Receptor, TIE-2 / antagonists & inhibitors*
-
Receptor, TIE-2 / metabolism
-
Structure-Activity Relationship
-
Xenograft Model Antitumor Assays
Substances
-
4-aminopyrrolopyrimidine
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Pyrroles
-
Receptor, TIE-2